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Abstract 
Objective: An increased slowing of cardiac conduction induced by sodium channel 
blockers is remarkably observed in carriers of an Asian-specific promoter haplotype 
(haplotype B, HapB) of the cardiac sodium channel (SCN5A) gene. We investigated the 
effect of HapB on the therapeutic range for serum flecainide concentration in Asian 
patients. 
Methods: We examined the serum concentration and anti-arrhythmic efficacy of 
flecainide, together with the SCN5A promoter haplotype, in 146 patients with 
supraventricular tachyarrhythmias. Trough serum flecainide concentrations were 
determined by HPLC. The anti-arrhythmic efficacy of flecainide was assessed for at 
least 2 months through examination of symptomatology, electrocardiograms, and Holter 
monitoring. 
Results: Serum flecainide concentration did not differ between wild-type haplotype A 
(HapA) homozygotes and HapB carriers under the treatment with usual dose. A genetic 
difference in the anti-arrhythmic efficacy of flecainide was observed between the HapA 
homozygotes and HapB carriers at serum flecainide concentrations <300 ng/mL (42.9% 
vs. 68.8%; P = 0.02). PR prolongation and QRS widening appeared more excessively in 
the HapB carriers with serum flecainide concentrations ≥300 ng/mL than in the HapA 
homozygotes (PR, 210 ± 25 vs. 195 ± 25 ms; P = 0.036; and QRS, 112 ± 10 vs. 105 ± 9 
ms; P = 0.030). 
Conclusions: These findings suggest that the therapeutic range for serum flecainide 
concentration is lower in HapB carriers than in HapA homozygotes. 
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Introduction 
The voltage-gated cardiac sodium channel type V alpha (SCN5A) is responsible for the 
fast depolarization upstroke of the cardiac action potential. It acts as a molecular target 
for anti-arrhythmic drugs [1]. Mutations in the SCN5A gene result in long QT 
syndrome, Brugada syndrome, atrial fibrillation, dilated cardiomyopathy, and sick sinus 
syndrome [2-10]. A haplotype B (HapB) consisting of 6 individual SCN5A promoter 
polymorphisms has been shown to produce lower SCN5A transcription activity in 
Asians (allele frequency 24%) [11]. Increased slowing of cardiac conduction induced by 
a sodium channel blocker challenge test was remarkably observed in HapB carriers 
compared with that in wild-type haplotype A (HapA) homozygotes [11]. Thus, SCN5A 
promoter haplotype status may modify a patient’s response to sodium channel blockers 
by modulating the activity of SCN5A [12]. The influence of HapB on the anti-
arrhythmic efficacy of the daily dosage of sodium channel blockers is unclear. 
 Flecainide acetate, a potent sodium channel blocker, is a class Ic anti-arrhythmic 
agent commonly used for treatment of a variety of supraventricular tachyarrhythmias 
[13-15]. Maintaining the serum flecainide concentration within the recommended 
therapeutic range (200–1000 ng/mL) provides proven efficacy without the development 
of severe adverse events such as proarrhythmia [16-18]. Severe adverse events have 
occasionally occurred in patients whose serum flecainide concentration exceeded 1000 
ng/mL [19]. The lower limit of the recommended therapeutic range for serum flecainide 
concentration, which remains somewhat controversial, varies from 200 to 400 ng/mL 
for suppression of ventricular arrhythmia [16, 18, 20]. We previously reported that the 
serum flecainide concentration was recommended to maintain ≥300 ng/mL in patients 
with supraventricular tachyarrhythmias [21-23]. However, according to a previous 
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report, some patients showed sufficient effectiveness of flecainide at concentrations 
<300 ng/mL [21]. We hypothesized that interindividual differences in the flecainide 
therapeutic concentration may result from differences in the activity of the drug target, 
such as reduction in sodium current density due to the presence of SCN5A promoter 
HapB. To confirm this hypothesis, we examined the effects of SCN5A promoter 
haplotype status on the therapeutic range for serum flecainide concentrations in Asian 
patients with supraventricular tachyarrhythmias.  
 
Methods 
Patients  
Patients treated with oral flecainide for supraventricular tachyarrhythmias were enrolled 
in this study during an outpatient visit to our hospital (Table 1). Exclusion criteria were 
as follows: history of unstable angina or myocardial infarction, recent cardiac surgery, 
higher-degree atrioventricular nodal block, pacemaker-dependent rhythms, permanent 
atrial fibrillation, Brugada syndrome, concomitant therapy including other class І anti-
arrhythmic drugs or amiodarone, and left ventricular dysfunction (i.e., ejection fraction 
<50% or history of heart failure or both). The patients had received oral flecainide (1.2–
5.0 mg/kg/day as flecainide acetate) for 2–100 months (mean, 18 ± 24 months). They 
received other drugs as per requirement: digoxin, β-blockers (carvedilol, atenolol, 
nadolol, bisoprolol, metoprolol, propranolol), Ca2+ antagonists (verapamil, diltiazem, 
nifedipine, amlodipine, nisoldipine, nicardipine), angiotensin-converting enzyme 
inhibitors (enalapril, lisinopril, temocapril), angiotensin II receptor blockers (valsartan, 
telmisartan, olmesartan, losartan, candesartan), anti-coagulants (warfarin, aspirin, 
ticlopidine), H2-blockers (famotidine, ranitidine), or other drugs (lipid-decreasing drugs, 
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HMG–CoA reductase inhibitors). This study was approved by the ethical committee of 
the University of Tsukuba (approval number, 63-1). Written informed consent was 
obtained from all patients. 
 
Sample collection and determination of serum flecainide  
The patients had received flecainide for at least 2 months prior to the study. Blood 
draws for determining flecainide trough levels were performed between 8:30 and 11:00 
during an outpatient visit. On sample collection days, the patients postponed taking their 
morning flecainide until after the collection. The last dose of flecainide before sample 
collection was 19:00–21:00. Serum samples separated from whole blood were stored at 
−20 °C until analysis. 
 Flecainide acetate and an internal standard [N-(2-piperidinylmethyl)-2,3-bis(2,2,2-
trifluoroethoxy)benzamide acetate] were kindly supplied by Eisai Co. (Tokyo, Japan). 
Serum flecainide was determined by HPLC on a conventional octadecylsilyl silica 
column with a fluorescence detector, as described previously [24]. Assay precision was 
evaluated by intra- and inter-day validation at 200 and 1000 ng/mL flecainide. The 
coefficients of variation for intra- and inter-day assays were 2.7%–5.3% and 7.0%–
8.4%, respectively 
 
Clinical evaluation of anti-arrhythmic efficacy  
The anti-arrhythmic efficacy of flecainide was assessed for at least 2 months through 
examination of symptomatology, 12-lead electrocardiograms, and Holter monitoring. At 
discharge, the patients were given a form and asked to record the incidence of 
subjective symptoms (e.g., palpitation, chest oppression, chest pain, shortness of breath, 
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and presyncope). Reported subjective symptoms and an electrocardiogram were 
recorded at each patient visit. For evaluation of arrhythmias (n = 49), Holter monitoring 
was performed for 24 h. Presence of arrhythmias was defined as occurrence of 
symptoms suggestive of tachycardia and an episode of arrhythmias documented on 
electrocardiogram or Holter monitoring during the assessment period.  
 
Genotyping of SCN5A promoter polymorphism and CYP2D6 polymorphism 
Genomic DNA was isolated from peripheral blood with an extraction kit (Takara Bio, 
Shiga, Japan).  
 Genotyping for SCN5A T-1418C and T-1062C was performed by restriction 
fragment length polymorphism analysis, as described previously [11]. The 
corresponding SCN5A gene fragments were amplified using the primers 5′-ACC TAA 
GGC GTC CAA CGA AGC-3′ (forward) and 5′-CCA GGG TCT CAG AGG GCA 
CAG-3′ (reverse) for T-1418C and 5′-CCC TGA TGG CCT GTT TTG TTT-3′ 
(forward) and 5′-ACT CAG AGA CAT GGT CAC AGG CA-3′ (reverse) for T-1062C. 
PCR amplification conditions were as follows: 94 °C for 4 min (initial denaturation); 
followed by 30 cycles of 94 °C for 30 s (denaturation), 59 °C for 30 s (annealing), and 
72 °C for 30 s (extension); and 72 °C for 2 min (final extension). DNA fragments 
generated after restriction enzyme (EarI for T-1418C and HaeIII for T-1062C) 
digestion were separated on a 4% agarose gel. These SNPs were used to assign SCN5A 
promoter haplotypes: A (-1418T and -1062T), B (-1418C and -1062C), and C (-1418C 
and -1062T). 
Genotyping for the SCN5A H558R polymorphism (1673A>G) was performed by 
restriction fragment length polymorphism analysis, as described previously, with minor 
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modifications [6]. The corresponding SCN5A gene fragment was amplified using the 
primers 5′-GAG ACC TGG GTT CTG AAG CA-3′ (forward) and 5′-TCA GTT TGG 
GAG ACC AGA CC-3′ (reverse). PCR amplification conditions were as follows: 94 °C 
for 4 min (initial denaturation); followed by 30 cycles of 94 °C for 30 s (denaturation), 
59 °C for 30 s (annealing), and 72 °C for 30 s (extension); and 72 °C for 2 min (final 
extension). DNA fragments generated after restriction enzyme (AciI) digestion were 
separated on 4% agarose gel.  
 CYP2D6*1, *2 (C2850T), *4 (G1846A), *5 (CYP2D6 gene deletion), *10 (C100T), 
*14 (G1758A), *21 (2573 C insertion), *36 (CYP2D6 gene conversion to CYP2D7P in 
exon 9), and CYP2D6xN (CYP2D6 gene duplication) were determined using allele-
specific polymerase chain reaction (PCR) with mismatch primers (ASPCR-MP) and 
step-down PCR [25]. SNP typing kits for cytochrome P450 (STK-121, 122, 124, 125, 
126 for ASPCR-MP; STK-123, 127, 128 for step-down PCR) were obtained from 
Toyobo (Tokyo, Japan). We designated CYP2D6*1 and *2 alleles as extensive 
metabolizer (EM) alleles, *10 as an intermediate metabolizer (IM) allele, and *4, *5, 
*14, *21, and *36 as poor metabolizer (PM) alleles. 
 
Statistical analyses  
Patient characteristics and pharmacokinetic and electrocardiographic data were 
compared between the HapA homozygotes and HapB carriers using Student’s t-test, 
Welch’s t-test, or the Mann–Whitney U-test. Comparison of proportions was performed 
using the chi-square test, Fisher’s exact probability test, or the Mann–Whitney U test. 
Observed haplotype pair frequencies were compared with those expected under the 
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Hardy–Weinberg equilibrium. P values <0.05 were considered statistically significant. 
 
Results 
SCN5A promoter polymorphisms and patient characteristics 
SCN5A promoter polymorphisms were examined in 146 patients treated with oral 
flecainide for supraventricular tachyarrhythmias. The frequencies of SCN5A promoter 
haplotype A, B, and C were 0.788, 0.205, and 0.007, respectively. The overall 
frequency of haplotypes genotyped in this study was comparable to that reported for the 
Japanese population [11]. The numbers of patients with each haplotype pair were as 
follows: 91 with AA, 47 with AB, 6 with BB, 1 with BC, and 1 with AC. The 
frequencies of haplotype pair were not different from the Hardy–Weinberg equilibrium 
(P = 0.78). 
 The 91 SCN5A promoter HapA homozygotes and 54 HapB carriers were used in 
the comparison. The lone patient with haplotype pair AC was excluded from the 
analysis. Patient characteristics for each haplotype group are summarized in Table 1. 
Sex, age, body weight, diagnosis of supraventricular tachyarrhythmias, and 
comorbidities did not significantly differ between the HapA homozygotes and HapB 
carriers (Table 1). The frequency of R558 polymorphism, a major SCN5A coding region 
polymorphism, did not differ significantly between the HapA homozygotes and HapB 
carriers (7.7% vs. 12.0%; P = 0.21). The frequencies of CYP2D6 polymorphisms did 
not differ between the HapA homozygotes and HapB carriers (Table 1). The flecainide 
daily dose did not differ between CYP2D6 EM allele homozygotes and IM/PM allele 
carriers in both HapA homozygotes (2.3 ± 0.8 vs. 2.4 ± 0.8 mg/kg; P = 0.49) and HapB 
10 
 
carriers (2.4 ± 0.8 vs. 2.4 ± 0.8 mg/kg; P = 0.77). 
 
SCN5A promoter haplotype and anti-arrhythmic efficacy of flecainide 
The flecainide daily dose and serum flecainide concentration did not differ significantly 
between the HapA homozygotes and HapB carriers (Table 2). Tachyarrhythmias were 
well controlled in 63.0% of the HapB carriers and 51.6% of the HapA homozygotes; 
this difference was not significant (P = 0.18; Table 2). The influence of the SCN5A 
promoter haplotype on the anti-arrhythmic efficacy of flecainide was compared between 
the patients with serum flecainide concentrations <300 ng/mL and ≥300 ng/mL 
according to the previous reports [21-23]. The HapB carriers achieved clinically 
relevant flecainide efficacy more frequently (68.8%) when the serum flecainide 
concentrations were <300 ng/mL, compared with the HapA homozygotes (42.9%; P = 
0.022; Table 2). The efficacy of flecainide at serum concentrations ≥300 ng/mL did not 
differ significantly between the 2 groups (54.5% vs. 61.9%; P = 0.57; Table 2).  
 The serum concentration–cumulative efficacy rate curves for prevention of 
supraventricular arrhythmias in the HapA homozygotes and HapB carriers are shown in 
Fig.1. The concentration–efficacy curve in the HapB carriers had a sharper increase at 
serum flecainide concentrations <300 ng/mL than that in the HapA homozygotes. The 
concentration–efficacy curve was shifted to the left in the HapB carriers compared with 
that in the HapA homozygotes; the cumulative efficacy rate (24%) at 300 ng/mL in the 
HapA homozygotes was achieved at around 200 ng/mL in the HapB carriers (Fig. 1). 
 Electrocardiographic data in sinus rhythm and the absence of bundle branch block 
under treatment with flecainide were compared between the HapA homozygotes (n = 
59) and HapB carriers (n = 39) (Table 3). No significant difference was observed in 
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heart rate, PR interval, QRS duration, and QTc interval between the HapA homozygotes 
and HapB carriers at serum flecainide concentrations <300 ng/mL (Table 3). In contrast, 
the PR interval and QRS duration were significantly prolonged in the HapB carriers 
compared with that in the HapA homozygotes at serum flecainide concentration ≥300 
ng/mL (P = 0.036 and P = 0.030, respectively, Table 3); however, the heart rate and 
QTc interval did not differ between the HapA homozygotes and HapB carriers.  
 
Discussion 
The present study revealed that an Asian-specific SCN5A promoter haplotype influences 
the anti-arrhythmic efficacy of daily doses of flecainide. HapB carriers obtained 
clinically relevant flecainide efficacy even at drug concentrations <300 ng/mL (Table 2 
and Fig. 1). This finding suggests that the therapeutic range for serum flecainide 
concentration was lower in the HapB carriers because of their low expression of 
SCN5A. Thus, a SCN5A promoter haplotype is an important factor for explaining the 
difference in flecainide efficacy at lower serum drug concentrations in Asian patients.  
 We previously reported that the serum flecainide concentration should be 
maintained at ≥300 ng/mL to control the paroxysms of supraventricular 
tachyarrhythmias [21-23]. The recommended serum flecainide concentration in Hap B 
carriers, however, is likely to be ≥200 ng/mL because the cumulative efficacy rate at 
around 200 ng/mL was similar to that at 300 ng/mL in the HapA homozygotes (Fig. 1). 
In contrast, electrocardiographic data associated with the risk of cardiovascular side 
effects [20] showed an excess of cardiac conduction slowing in the HapB carriers with 
serum flecainide concentrations ≥300 ng/mL; the PR interval (210 ± 25 ms) and QRS 
duration (112 ± 10 ms) were significantly longer than those in the HapA homozygotes 
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(Table 3). These values were also remarkable when compared with the data from 
postmarketing surveillance of flecainide acetate in Japanese patients with atrial 
fibrillation/flutter (PR interval: 183 ± 34 ms, and QRS duration: 102 ± 20 ms) [26]. The 
upper limit of the therapeutic range for serum flecainide concentration may also be 
lower in HapB carriers because of excess slowing in cardiac conduction.  
 Many factors can influence the anti-arrhythmic effects of sodium channel blockers. 
The variability in SCN5A function due to polymorphisms in the SCN5A coding region 
may be a genetic factor explaining the interindividual difference in the anti-arrhythmic 
efficacy. A common polymorphism in the SCN5A coding region such as H558R, a risk 
factor for lone atrial fibrillation, may contribute to the drug response observed with 
sodium channel blockers. [6, 7] However, in the present study, the frequency of the 
R558 polymorphism is similar between the HapA homozygotes and HapB carriers. The 
other genetic factor may be the variant in MOG1, a cofactor of the cardiac sodium 
channel, which regulates the channel expression on surface of the cardiomyocytes and 
reduces the sodium current. [27, 28] Although other factors such as concomitant anti-
arrhythmic drugs can influence the prevention of supraventricular tachyarrhythmias, 
coadministration of digoxin, β-blockers, and Ca2+ antagonists did not differ between the 
2 groups in the present study (Table 1). 
 Our study has several limitations for assessment of clinical efficacy and a gene-
dose effect in ECG parameter. Firstly, asymptomatic atrial fibrillation could not be 
detected in every patient because Holter monitoring was available in one-third of the 
present patients. Second, a clear gene-dose effect in PR interval and QRS duration was 
not found in the present study because the number of HapB homozygotes was 
insufficient. 
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 In Japan, the flecainide acetate package insert recommends an initial dose of 100 
mg/day. This recommendation may be reasonable because one-third of Japanese 
patients are HapB carriers in whom clinically relevant flecainide efficacy is obtained at 
lower serum concentrations. Another Asian-specific genetic factor affecting flecainide 
efficacy is CYP2D6*10, a polymorphism in the gene encoding the main metabolic 
enzyme for flecainide. Since about 60% of Japanese patients were reported to be 
CYP2D6*10 carriers [29], this variant as well as the SCN5A promoter HapB may result 
in a lower flecainide dose requirement in this population [30, 31]. 
  In conclusion, HapB carriers more frequently achieve clinically relevant 
flecainide efficacy even at lower concentrations. The present study suggests that the 
therapeutic range for serum flecainide concentration in HapB carriers is likely to be 
lower than that in HapA homozygotes.  
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Figure legend 
Fig. 1   Serum concentration–cumulative efficacy rate curves for prevention of 
supraventricular arrhythmias in HapA homozygotes and HapB carriers. The 
cumulative efficacy rate was calculated as the percentage of effective patients 
accumulated up to each serum flecainide concentration in each patient group. 
 

Table 1   Patient characteristics 
 
      
Hap A 
homozygotes 
Hap B 
carriers 
P-value 
Number of patients 91   54     
Female sex 20 (22.0%) 11 (20.4%) 0.82 
Age (y) 61.2 ± 11.3 60.4 ± 14.0 0.91 
Weight (kg) 67.2 ± 10.7 64.1 ± 10.8 0.096 
Diagnosis           
  Paroxysmal atrial fibrillation 67 (73.6%) 46 (85.2%) 0.42  
  Persistent atrial fibrillation 7 (7.7%) 4 (7.4%)   
 
Paroxysmal atrial fibrillation  
and atrial flutter 
10 (11.0%) 2 (3.7%) 
  
  Paroxysmal supraventricular tachycardia 6 (6.6%) 2 (3.7%)   
  Wolff-Parkinson-White syndrome 1 (1.1%) 0 (0%)   
Comorbidities           
  Hypertension 49 (53.8%) 20 (37.0%) 0.050  
  Hyperlipidemia 24 (26.4%) 14 (25.9%) 0.95 
  Diabetes mellitus 17 (18.7%) 8 (14.8%) 0.55 
  Chronic kidney disease 18 (19.8%) 10 (18.5%) 0.85 
Concomitant anti-arrhythmic drugs           
  Digoxin 7 (7.7%) 8 (14.8%) 0.17 
  β blockers 51 (56.0%) 26 (48.1%) 0.36 
 
Ca2+ antagonists 17 (18.7%) 8 (14.8%) 0.55 
CYP2D6 allele frequency 
     
 
EM allele 60.4% 57.4% 0.88 
 
IM allele 36.2% 38.9% 
 
 
PM allele 3.3% 3.7% 
 
Data are presented as number (percentage), mean ± SD or percentage. CYP2D6*1 and *2 
alleles, extensive metabolizer (EM) alleles; *10, an intermediate metabolizer (IM) allele; *4, *5, 
*14, *21, and *36, poor metabolizer (PM) alleles. 
Table 2  Effect of SCN5A promoter haplotype on anti-arrhythmic efficacy of flecainide 
 
      
Hap A 
homozygotes 
Hap B  
carriers 
P-value 
Number of patients 91 54   
Flecainide daily dose (mg/kg) 2.34 ± 0.78 2.39 ± 0.83 0.81 
Seurm flecainide concn. (ng/mL) 300 ± 154 309 ± 161 0.74 
Efficacy of flecainide (effective / ineffective)           
  Overall 47 / 44 (51.6%) 34 / 20 (63.0%) 0.18 
  Serum flecainide concn. of <300 ng/mL 21 / 48 (42.9%) 22 / 10 (68.8%) 0.022 
  Serum flecainide concn. of ≥300 ng/mL 26 / 16 (61.9%) 12 / 10 (54.5%) 0.57 
Data are presented as number, mean ± SD or number (efficacy rate). 
Table 3  Effects of SCN5A promoter haplotype on ECG data in sinus rhythm under treatment 
with flecainide 
 
      
Hap A 
homozygotes 
Hap B  
carriers 
P-value 
Number of patients with ECG data in sinus rhythm 59 39   
  Serum flecainide concn. of <300 ng/mL 27 23   
    Heart rate (beats/min) 61 ± 8 63 ± 10 0.47 
    PR interval (ms) 178 ± 20 181 ± 25 0.66 
    QRS duration (ms) 101 ± 8 102 ± 8 0.63 
    QTc 422 ± 29 419 ± 27 0.90 
  Serum flecainide concn. of ≥300 ng/mL 32 16   
    Heart rate (beats/min) 60 ± 10 62 ± 10 0.57 
    PR interval (ms) 195 ± 25 210 ± 25 0.036 
    QRS duration (ms) 105 ± 9   112 ± 10 0.030 
    QTc 437 ± 23 434 ± 24 0.69 
Data are presented as number or mean ± SD. ECG, electrocardiogram. 
